초록 close

Background and Objectives:by a tumor, and many types of vaccines such as gene modified vaccines have been developed to increase imunogenicity of vaccine. We studied to determine whether or not 5-aza-2-deoxycytidine (ADC) can increase the immunogenicity of B16F10 melanoma cell. Materials and Method:B16F10 cell was treated with ADC for the induction of DNA demethylation. An ADC treated B16F10 melanoma cell was analyzed first using the reverse transcriptase-polymerase chain reaction (RT-PCR) (MAGE-2, MAGE-5) and immunity-enhancing cytokines (GM-CSF, IL-12), and then by flow cytometry to evaluate the expression of MHC and B7 that are responsible for antigen expres-sion and T cell activation on B16F10 cell surface. In order to evaluate vaccination effect of ADC-treated B16F10 vaccine, each mouse group were injected with PBS, ADC, B16F10 vaccine or B16F10-ADC vaccine and they were also challenged with live B16F10 cell 7 days after vaccination. On the 20th day after live B16F10 cell challenge, the tumor mass size and the Results:ADC treatment for B16F10 melanoma cell increased expresion of MHC and B7. ADC treatment also increased gene expresion of MAGE-2, MAGE-5, GM-CSF and IL-12. The growth of tumor mass was decreased and the mouse survival period was elongated in B16F10-ADC vaccine imunized group. Conclusion:ADC treatment may increase imunogenicity of B16F10 cell, and B16F10-ADC vaccine imunization can induce anti-cancer imunity in vivo. (Korean J Otolaryngol 2002;45:784-90)